Peak Bio, Inc.

Peak Bio, Inc., trading under the ticker IGNY, filed an 8-K with the SEC on March 5, 2024, reflecting continued corporate activity following the company's de-SPAC transaction with Ignyte Acquisition Corp. Ignyte Acquisition Corp completed its initial public offering in 2021, targeting the life sciences and biopharmaceutical sector. The resulting combined entity, Peak Bio, operates in oncology drug development, focusing on next-generation antibody-drug conjugate therapeutics. The March 2024 filing represents post-merger disclosure obligations under the Exchange Act, as the company navigates its public-company lifecycle following the business combination. Visit SpacDesk and sign up for full access to IGNY filings, deal timelines, and sponsor analytics.